ArticleHeliyon2024
SurvNet: A low-complexity convolutional neural network for survival time classification of patients with glioblastoma.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- AI for prognosis and treatment stratification in glioblastoma neurosurgery: a systematic review.Journal of neuro-oncology · 2026Pooled it
- Application of artificial intelligence in forecasting survival in high-grade glioma: systematic review and meta-analysis involving 79,638 participants.Neurosurgical review · 2025Pooled it
- Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.BMC cancer · 2024Pooled it
- Explainability and Clinical Trust of Deep Learning in Glioblastoma Treatment Efficacy Prediction: A Comprehensive Framework.Journal of imaging informatics in medicine · 2026Article
- A twin-tower model using MRI and gene for prediction on brain tumor patients' response to therapy.Bioinformatics advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Malignant primary brain tumors cause the greatest number of years of life lost than any other cancer. Grade 4 glioma is particularly devastating: The median survival without any treatment is less than six months and with standard-of-care treatment is only 14.6 months. Accurate identification of the overall survival time of patients with brain tumors is of profound importance in many clinical applications. Automated image analytics with magnetic resonance imaging (MRI) can provide insights into the prognosis of patients with brain tumors. Methods: In this paper, We propose SurvNet, a low-complexity deep learning architecture based on the convolutional neural network to classify the overall survival time of patients with brain tumors into long-time and short-time survival cohorts. Through the incorporation of diverse MRI modalities as inputs, we facilitate deep feature extraction at various anatomical sites, thereby augmenting the precision of predictive modeling. We compare SurvNet with the Inception V3, VGG 16 and ensemble CNN models on pre-operative magnetic resonance image datasets. We also analyzed the effect of segmented brain tumors and training data on the system performance. Results: Several measures, such as accuracy, precision, and recall, are calculated to examine the perfor-mance of SurvNet on three-fold cross-validation. SurvNet with T1 MRI modality achieved a 62.7 % accuracy, compared with 52.9 % accuracy of the Inception V3 model, 58.5 % accuracy of the VGG 16 model, and 54.9 % of the ensemble CNN model. By increasing the MRI input modalities, SurvNet becomes more accurate and achieves 76.5 % accuracy with four MRI modalities. Combining the segmented data, SurvNet achieved the highest accuracy of 82.4 %. Conclusions: The research results show that SurvNet achieves higher metrics such as accuracy and f1-score than the comparisons. Our research also proves that by using multiparametric MRI modalities, SurvNet is able to learn more image features and performs a better classification accuracy. We can conclude that SurvNet with the complete scenario, i.e., segmented data and four MRI modalities, achieved the best accuracy, showing the validity of segmentation information during the survival time prediction process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.